Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.

NCT07344519 is registered in ClinicalTrials.gov with ExoRNA Bioscience as lead sponsor.

NCT NCT07344519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07344519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Dose Escalation Early Phase 1 Study of ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease.
Lead sponsor
ExoRNA Bioscience
Phase
Phase 1
Overall status
Completed
Start date
June 25, 2024
Completion date
January 31, 2026
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease